Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant rise in the number of TC cases has been observed for the past few decades. TCs are one of the most frequent tumors in younger adults, especially in women, therefore early diagnosis and effective therapy are espec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maciej Ratajczak, Damian Gaweł, Marlena Godlewska
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	thyroid cancer targeted therapies kinase inhibitors RAI-refractory Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/ea69f592d85146938c7e29fb96bf3eaf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea69f592d85146938c7e29fb96bf3eaf
record_format	dspace
spelling	oai:doaj.org-article:ea69f592d85146938c7e29fb96bf3eaf2021-11-11T17:15:52ZNovel Inhibitor-Based Therapies for Thyroid Cancer—An Update10.3390/ijms2221118291422-00671661-6596https://doaj.org/article/ea69f592d85146938c7e29fb96bf3eaf2021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11829https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant rise in the number of TC cases has been observed for the past few decades. TCs are one of the most frequent tumors in younger adults, especially in women, therefore early diagnosis and effective therapy are especially important. Ultrasonography examination followed by fine needle biopsy have become the gold standard for diagnosis of TCs, as these strategies allow for early-stage detection and aid accurate qualification for further procedures, including surgical treatment. Despite all the advancements in detection and treatment of TCs, constant mortality levels are still observed. Therefore, a novel generation line of targeted treatment strategies is being developed, including personalized therapies with kinase inhibitors. Recent molecular studies on TCs demonstrate that kinase inhibitor-based therapies might be considered as the most promising. In the past decade, new kinase inhibitors with different mechanisms of action have been reported and approved for clinical trials. This review presents an up-to-date picture of new approaches and challenges of inhibitor-based therapies in treatment of TCs, focusing on the latest findings reported over the past two years.Maciej RatajczakDamian GawełMarlena GodlewskaMDPI AGarticlethyroid cancertargeted therapieskinase inhibitorsRAI-refractoryBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11829, p 11829 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	thyroid cancer targeted therapies kinase inhibitors RAI-refractory Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	thyroid cancer targeted therapies kinase inhibitors RAI-refractory Biology (General) QH301-705.5 Chemistry QD1-999 Maciej Ratajczak Damian Gaweł Marlena Godlewska Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
description	Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant rise in the number of TC cases has been observed for the past few decades. TCs are one of the most frequent tumors in younger adults, especially in women, therefore early diagnosis and effective therapy are especially important. Ultrasonography examination followed by fine needle biopsy have become the gold standard for diagnosis of TCs, as these strategies allow for early-stage detection and aid accurate qualification for further procedures, including surgical treatment. Despite all the advancements in detection and treatment of TCs, constant mortality levels are still observed. Therefore, a novel generation line of targeted treatment strategies is being developed, including personalized therapies with kinase inhibitors. Recent molecular studies on TCs demonstrate that kinase inhibitor-based therapies might be considered as the most promising. In the past decade, new kinase inhibitors with different mechanisms of action have been reported and approved for clinical trials. This review presents an up-to-date picture of new approaches and challenges of inhibitor-based therapies in treatment of TCs, focusing on the latest findings reported over the past two years.
format	article
author	Maciej Ratajczak Damian Gaweł Marlena Godlewska
author_facet	Maciej Ratajczak Damian Gaweł Marlena Godlewska
author_sort	Maciej Ratajczak
title	Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
title_short	Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
title_full	Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
title_fullStr	Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
title_full_unstemmed	Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
title_sort	novel inhibitor-based therapies for thyroid cancer—an update
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ea69f592d85146938c7e29fb96bf3eaf
work_keys_str_mv	AT maciejratajczak novelinhibitorbasedtherapiesforthyroidcanceranupdate AT damiangaweł novelinhibitorbasedtherapiesforthyroidcanceranupdate AT marlenagodlewska novelinhibitorbasedtherapiesforthyroidcanceranupdate
_version_	1718432152778964992

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Ejemplares similares